• Blueprint Medicines average ebitda margin for 2023 was -234.02%, a 14.8% decline from 2022.
• Blueprint Medicines average ebitda margin for 2022 was -274.66%, a 69.44% decline from 2021.
• Blueprint Medicines average ebitda margin for 2021 was -162.1%, a 34.14% increase from 2020.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.